Table 1. Association between expression of BRD7, mature miR-141 and NPC clinical pathological features (N=104).
|
BRD7 |
miR-141 |
BRD7/miR-141a |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristics (N) | H (%) | L (%) | P-value | H (%) | L (%) | P-value | H-L (%) | L-H (%) | P-value |
| Age (year) | |||||||||
| ≤40 (n=27) | 10 (37.0) | 17 (63.0) | 0.576 | 18 (66.7) | 9 (33.3) | 0.452 | 7 (25.9) | 16 (59.3) | 0.764 |
| >40 (n=77) | 24 (31.2) | 53 (68.8) | 45 (58.4) | 32 (41.6) | 19 (24.7) | 37 (48.1) | |||
| Gender | |||||||||
| Female (n=23) | 6 (26.1) | 17 (73.9) | 0.384 | 13 (56.5) | 10 (43.5) | 0.652 | 5 (21.7) | 12 (52.2) | 0.759 |
| Male (n=81) | 29 (35.8) | 52 (64.2) | 50 (61.7) | 31 (38.3) | 21 (25.9) | 42 (51.9) | |||
| Histological type | |||||||||
| DNC (n=6) | 2 (33.3) | 4 (66.7) | 0.986 | 3 (50.0) | 3 (50.0) | 0.585 | 2 (33.3) | 3 (50.0) | 0.776 |
| UDNC (n=98) | 33 (33.7) | 65 (66.3) | 60 (61.2) | 38 (38.8) | 26 (26.5) | 51 (52.1) | |||
| Clinical stages | |||||||||
| Stage I (n=14) | 8 (57.1) | 6 (42.9) | 0.004 | 5 (35.7) | 9 (64.3) | 0.003 | 6 (42.9) | 3 (21.4) | 0.0004 |
| Stage II (n=33) | 14 (42.4) | 19 (57.6) | 13 (39.4) | 20 (60.6) | 12 (36.4) | 12 (36.4) | |||
| Stage III (n=39) | 12 (30.8) | 27 (69.2) | 27 (69.2) | 12 (30.8) | 8 (20.5) | 24 (61.5) | |||
| Stage IV (n=18) | 2 (11.1) | 16 (88.9) | 13 (72.2) | 5 (27.8) | 1 (55.6) | 13 (72.2) | |||
Abbreviations: DNKC, differentiated non-keratinized nasopharyngeal carcinoma; UDNC, undifferentiated non-keratinized nasopharyngeal carcinoma; H, high expression; L, low expression
a
H-L, High expression of BRD7 and low expression of miR-141; L-H, Low expression of BRD7 protein and high expression of miR-141